Losartan in diabetic nephropathy

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 4, 2004, Pages 473-483

  Perico, Norberto ^a   Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Angiotensin antagonist; Angiotensin converting enzyme inhibitor; Chronic kidney disease; Cozaar; Diabetes; Diabetic nephropathy; Losartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM;

ABDOMINAL PAIN; ANEMIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COST CONTROL; COUGHING; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; EDEMA; FATIGUE; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; MICROALBUMINURIA; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; PRIMARY PREVENTION; PROTEINURIA; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN;

EID: 4043104935     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.4.473     Document Type: Article

References (100)

1. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end stage renal disease in the united states to the year 2010. J. Am. Soc. Nephrol. 12, 2753-2758 (2001).
2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. 13, S37-S40 (2002).
3. Ansell D, Feest T, Byrne C. UK Renal Registry Report 1999. Anselt D, Feest T (Eds), UK Renal Registry, Bristol, UK (1999).
4. Schaubel D, Morrison H, Desmeules M et al. End stage renal disease in Canada: prevalence projections to 2005. Can. Med. Assoc. J. 160, 1557-1563 (1999).
5. US Renal Data System. Excerpts from the USRDS annual data report. Am. J. Kidney Dis. 36(Suppl.), S1-S239 (2000).
6. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient? Diabetes 49, 1399-1408 (2000).
7. National Diabetes Data Group: Diabetes in America, 2nd Edition. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication, ND, USA 95-1468 (1995).
8. Mogensen CE, Chachati A, Christensen CK et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 9, 85-95 (1985).
9. Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. J. Am. Med. Assoc. 236, 1861-1863 (1976).
10. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: The Kidney Brenner BM (Ed.), WB Saunders, PA, USA (2000).
11. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand. J. Clin. Lab. Invest. 36, 383-388 (1976).
12. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetes with diabetic nephropathy. Diabetologia 20, 457-461 (1981).
13. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br. Med. J. 294, 1651-1654 (1987).
14. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes 44, 1303-1309 (1995).
15. Parving H-H, Hommel E. Prognosis in diabetic nephropathy. Br. Med. J. 299, 230-233 (1989).
16. Parving H-H, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1(8335), 1175-1179 (1983).
17. Lewis E, Hunsicker L, Bain B, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993).
18. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
19. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
20. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H. Effects of Losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
21. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Remission and regression in the nephropathy of Type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 60, 277-283 (2001).
22. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339, 1448-1456 (1998).
23. Abbate M, Zoja C, Morigi M et al. In progressive nephropathy, exuberant podocyte TGFβ activates a prosclerosis phenotype in mesangial cells. J. Am. Soc. Nephrol. 12, (2001) (Abstract 670A).
24. Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells. J. Am. Soc. Nephrol. 14, S36-S41 (2003).
25. Eddy AA. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 37(Suppl. 2), S25-S29 (2001).
26. Johnson DW, Saunders HJ, Baxter RC et al. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 54, 747-757 (1998).
27. Ruggenenti P, Perna A, Mosconi L et al. Urinary protein excretion rate is the best independent predictor to ESRF in nondiabetic chronic nephropathies. Kidney Int. 53, 1209-1216 (1998).
28. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 63, 1468-1474 (2003).
29. Rossing P, Hommel E, Smidt UM, Parving H-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42, 715-719 (1993).
30. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end stage renal disease in patients with Type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 63, 1499-1507 (2003).
31. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann. Intern. Med. 123, 754-762 (1995).
32. The GISEN Group (Gruppo Italiano, di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 349, 1857-1863 (1997).
33. Ruggenenti P, Perna A, Gherardi G et al., on behalf of Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352, 1252-1256 (1998).
34. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int. 45(Suppl. 4), S174-S178 (1994).
35. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int. 59, 702-709 (2001).
36. de Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 354, 352-353 (1999).
37. Ruggenenti P, Perna A, Remuzzi G. GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63, 2254-2261 (2003).
38. Aros C, Remuzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J. Hypertens. 20(Suppl. 3), S45-S53 (2002).
39. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I. Role of abnormally high transmural pressure in permselectivity defect of glomerular capillary wall: a study in early Heymann nephritis. Circ. Res. 61, 531-538 (1987).
40. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. Nephrol. 7, 653-660 (1996).
41. Kritz W, Hackenthal E, Nobiling R, Sakai T, Elger M. A role for podocytes to counteract capillary wall distension. Kidney Int. 45, 369-376 (1994).
42. Duvarsula RV, Petermann AT, Hiromura K et al. Activation of a local angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39 (2004).
43. Shake JG, Brandt RC, Daniels BS. Angiotensin II induces actin polymerization within glomerular filtration barrier: possible role in the local regulation of ultrafiltration. J. Am. Soc. Nephrol. 3, 568A (1992).
44. Gloy J, Henger A, Fischer K-G et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J. Clin. Invest. 99, 2772-2781 (1997).
45. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Dial. Transplant. 15(Suppl. 6), 61-63 (2000).
46. Wolf G, Ziyadeh F. Renal tubular hypertrophy induced by angiotensin II. Seminar Nephrol. 17, 448-454 (1997).
47. Wolf G, Kalluri R, Ziyadeh F, Neilson E, Stahl R. Angiotensin II induces α3 (IV) collagen expression in cultured urine proximal tubular cells. Proc. Assoc. Am. Physic. 11, 357-364 (1999).
48. Strutz F, Muller GA. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press. Res. 22, 71-80 (1999).
49. Baricos WH, Cortez SL, El-Dahr SS, Schaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 47, 1039-1047 (1995).
50. Keane WF, Rai JL. Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules. Lab. Invest. 52, 899-604 (1985).
51. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 49, 578-597 (1996).
52. Okada H, Danoff T, Kalluri R, Neilson E. Early role of Fsp 1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563-F574 (1997).
53. Rhaleb NE, Rouissi N, Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 14, 480-484 (1991).
54. Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drug Aging 16, 227-250 (2000).
55. Sica DA, Lo MW, Shaw WC et al. The pharmacokinetics of losartan in renal insufficiency. J. Hypertens. 13(Suppl. 1), S49-S52 (1995).
56. Sica DA, Halstenson CE, Gehr TW et al. Pharmacokinetics and blood pressure response of losartan in end stage renal disease. Clin. Pharmacokinet. 38, 519-526 (2000).
57. Ooak KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51, 820-845 (1996).
58. Merck & Co. Cozaar product monograph. (2001).
59. Cheetman C, O'Driscoll O, Stanton K et al. Losartan, an angiotensin Type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin. Sci. 100, 13-17 (2001).
60. Devereux RB, Dahlöf B, Kjeldsen SE et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. 139, 169-177 (2003).
61. Deininger E, Oltmanns KM, Wellhoener P et al. Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans. Clin. Pharmacol. Ther. 70, 362-369 (2001).
62. Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 month study. Nephrol. Dial. Transplant. 12(Suppl. 2), 19-13 (1997).
63. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int. 58, 762-769 (2000).
64. Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in Type 2 diabetic patients with microalbuminuria. Diabetes Metab. Res. Rev. 28, 71-76 (2002).
65. de Pablos-Velasco PL, Pazos Total F, Esmatjes JE et al. Losartan titration versus diuretic combination in Type 2 diabetic patients. J. Hypertens. 20, 715-719 (2002).
66. Zandbergen AAM, Baggen MGA, Lamberts SWJ, Bootsma AH, de Zeeuw D, Ouwendijk RJT. Effect of losartan on microalbuminuria in normotensive patients with Type 2 diabetes mellitus. Ann. Intern. Med. 139, 90-96 (2003).
67. Arteaga J, Petrina E, Anda E et al. The antiproteinuric effect of enalapril is potentiated by losartan in normotensive patients with diabetic nephropathy. Am. J. Hypertens. 13(Pt 2), 117 (2000).
68. 1RB and ACE-I has a synergic effect on the reduction of microalbuminuria in Type 2 diabetic patients. Diabetologia 44(Suppl. 1), 276 (2001).
69. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving H-H. Time course of antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol. Dial. Transplant. 18, 293-297 (2003).
70. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal hemodynamic responses to losartan in microalbuminuric IDDM. Nephrol. Dial. Transplant. 16, 771-775 (2001).
71. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H-H. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57, 601-606 (2000).
72. Parving H-H, Andersen S, Jacobsen P et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminar Nephrol. 24, 147-157 (2004).
73. Andersen S, Rossing P, Juhl TR, Deinum J, Parving H-H. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol. Dial. Transplant. 17, 1413-1418 (2002).
74. Parving H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. Br. Med. J. 313, 591-594 (1996).
75. Jacobsen P, Rossing K, Rossing P et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 53, 1002-1006 (1998).
76. Penno G, Chaturvedi N, Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47, 1507-1511 (1998).
77. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving H-H. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2843-2850 (2003).
78. Andersen S, Tarnow L, Cambien F et al. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26, 1501-1506 (2003).
79. Andersen S, Tarnow L, Cambien F et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int. 62, 192-198 (2002).
80. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. (Suppl. 45), S150-S155 (1994).
81. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 50, 1641-1650 (1996).
82. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Lancet 355, 253-259 (2000).
83. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving H-H. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46, 1182-1188 (1997).
84. Fogari R, Zoppi A, Corradi L et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with Type II diabetes and impaired renal function. J. Hum. Hypertens. 13, 47-53 (1999).
85. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care 23(Suppl. 2), SB54-SB64 (2000).
86. Merck & Co. Inc. FDA Advisory Committee recommends approval for Cozaar to delay progression of renal disease in Type 2 diabetic patients with proteinuria. Media Release 12, (2002).
87. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 25(Suppl. 1), S33-S49 (2002).
88. Herman WH, Shahinfar S, Carides GW et al., for the RENAAL Investigators. Losartan reduces the costs associated with diabetic end stage renal disease. Diabetes Care 26, 683-687 (2003).
89. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77, 1925-1930 (1986).
90. Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. Nephrol. 4, 40-49 (1993).
91. Jafar TH, Schmid CH, Landa M et al., for the Ace Inhibition in Progressive Renal Disease Study Group: angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann. Intern. Med. 135, 73-87 (2001).
92. Parving H-H. Diabetic nephropathy: prevention and treatment. Kidney Int. 60, 2041-2055 (2001).
93. Ruggenenti P, Mosconi L, Sangalli F et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 55, 984-994 (1999).
94. Chan JCN, Wat NMS, Therefore W-Y et al. Renin angiotensin aldosterone system blockade and renal disease in patients with Type 2 diabetes. An Asian perspective from the RENAAL study. Diabetes Care 27, 874-879 (2004).
95. Ruggenenti P, Perna A, Remuzzi G, on behalf of Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). ACE inhibitors to prevent end stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J. Am. Soc. Nephrol. 12, 2832-2837 (2001).
96. Hostetter TH. The next treatments of chronic kidney disease: if we find them, can we test them? J. Am. Soc. Nephrol. 13, 3024-3026 (2002).
97. Buckalew V, Martinez F, Altamirano J, Roniker J, Kleiman J, Krause S. The selective aldosterone blocker eplerenone is effective as monotherapy or adjunctive therapy in diabetic hypertensive with microalbuminuria. Diabetes 51(Suppl. 2), A38 (2002).
98. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608 (2001).
99. Orth SR, Stockmann A, Conradt C. Smoking as a risk factor for end stage renal failure in men with primary renal disease. Kidney Int. 54, 926-931 (1998).
100. Pechter U, Ots M, Mesikepp S, Zilmer K et al. Beneficial effects of water-based exercise in patients with chronic kidney disease. Int. J. Rehabil. Res. 26, 153-156 (2003).